Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kjekshus

Showing results (11-20 of 162) with videos related to

Pageof 17
Sort By:
European Heart Journal|December 1, 1987
Heart rate reduction--a mechanism of benefit?J Kjekshus
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 31, 1997
[Lipid reduction--benefit without risk?]J Kjekshus
Drugs|January 1, 1990
Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trialK Swedberg, J Kjekshus
Journal of Internal Medicine|April 1, 1996
Treatment of heart failureJ Kjekshus, K Swedberg
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 20, 1992
[Sudden cardiac death. Significance of beta blockaders]L Gullestad, J Kjekshus
Hormone and Metabolic Research. Supplement Series|January 1, 1985
Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarctionT Gundersen, J Kjekshus
The American Journal of Cardiology|February 21, 1989
Enalapril for congestive heart failureJ Kjekshus, K Swedberg
Clinical Cardiology|February 1, 1985
The importance of pre- and postinfarction angina on timolol-related reduction in mortality and reinfarctionT Gundersen, J Kjekshus
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 20, 1992
[Myocardial disease in diabetes mellitus]L Gullestad, J Kjekshus
The American Journal of Cardiology|March 16, 2001
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist LosartanK Dickstein, J Kjekshus,
Pageof 17

Showing results (11-20 of 162) with videos related to

Sort By:
Pageof 17
European Heart Journal|December 1, 1987
Heart rate reduction--a mechanism of benefit?J Kjekshus
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 31, 1997
[Lipid reduction--benefit without risk?]J Kjekshus
Drugs|January 1, 1990
Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trialK Swedberg, J Kjekshus
Journal of Internal Medicine|April 1, 1996
Treatment of heart failureJ Kjekshus, K Swedberg
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 20, 1992
[Sudden cardiac death. Significance of beta blockaders]L Gullestad, J Kjekshus
Hormone and Metabolic Research. Supplement Series|January 1, 1985
Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarctionT Gundersen, J Kjekshus
The American Journal of Cardiology|February 21, 1989
Enalapril for congestive heart failureJ Kjekshus, K Swedberg
Clinical Cardiology|February 1, 1985
The importance of pre- and postinfarction angina on timolol-related reduction in mortality and reinfarctionT Gundersen, J Kjekshus
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 20, 1992
[Myocardial disease in diabetes mellitus]L Gullestad, J Kjekshus
The American Journal of Cardiology|March 16, 2001
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist LosartanK Dickstein, J Kjekshus,
Pageof 17